Arizona Liver Health

Recent papers from Arizona Liver Health

1. Phase 1b study of miricorilant in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH)Hepatology · 2026
2. Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet · 2025
3. Oral GLP ‐ 1RA TERN ‐601 for Adults With Obesity/Overweight: Placebo‐Controlled, Multiple‐Ascending‐Dose, Phase 1 and 2 StudiesObesity · 2026
4. Poor overall performance of the resmetirom NIT algorithm: a multinational comparison across four tertiary care centers in Germany, Türkiye, and the United States2026
5. Ending the Chronic Liver Disease Public Health Threat: Systemic Challenges Through the Patient LensThe Lancet Regional Health - Europe · 2026
6. Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH)Drug Design Development and Therapy · 2026
7. Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. citiesAnnals of Hepatology · 2026
8. Diagnostic Accuracy of Noninvasive Tests for Metabolic Dysfunction-associated Steatotic Liver Disease Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational StudyClinical Gastroenterology and Hepatology · 2026
9. mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged ≥50 YearsOpen Forum Infectious Diseases · 2026
10. Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD studyHepatology · 2025
11. Optimizing clinic consultations in primary biliary cholangitis: International consensus recommendationsHepatology Communications · 2025
12. Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 DiabetesJAMA Network Open · 2025
13. Global performance of non-invasive tests in MASLD: Insights from the G-MASLD studyHepatology · 2025
14. P4 Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis2025
15. The association between neighborhood context, allostatic load, and metabolic dysfunction-associated steatosis liver disease in Mexican-origin farmworkers along the Southern Arizona US/Mexico borderSSM - Population Health · 2025
16. Resmetirom-eligible population among US adults: An estimation analysis based on NHANES 2017–March 2020Hepatology Communications · 2025
17. TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trialNature Medicine · 2025
18. Cardiac and liver impairment on multiorgan MRI and risk of major adverse cardiovascular and liver eventsNature Medicine · 2025
19. Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction–associated steatotic liver diseaseHepatology Communications · 2025
20. The emerging role of second harmonic generation/two photon excitation for precision digital analysis of liver fibrosis in MASH clinical trialsJournal of Hepatology · 2025